facebook-pixel

Exclusive: Feds accuse Utah pharmacy CEO of getting mislabeled hydroxychloroquine from China

Draper-based Meds In Motion won a no-bid state contract worth $800,000 before the state killed the deal.

(Rick Egan | The Salt Lake Tribune file photo) Dan Richards, CEO of Meds In Motion Pharmacy, speaks about the fight against the coronavirus at the Utah Capitol, Friday, March 20, 2020. Richards is now accused of receiving the controversial coronavirus drug hydroxychloroquine from an unregistered manufacturer in China, in April 2020 shipments that were labeled as an herbal supplement.